司美格鲁肽的益处，已远远超出了我们最初的想象

Core Viewpoint - Semaglutide, known as Wegovy and Ozempic, has significant benefits in reducing mortality rates from various causes, potentially transforming healthcare by promoting longevity and health [2][3][5]. Group 1: Research Findings - A recent study indicates that semaglutide can lower the risk of death from various causes, not just cardiovascular issues, highlighting its broader health benefits [5][9]. - The Select trial involved 17,604 overweight or obese participants aged 45 and older with cardiovascular disease but without diabetes, tracking them for over three years [7]. - Among the 833 deaths during the study, 58% were due to cardiovascular causes, while 42% were from other causes, with infections being the most common non-cardiovascular cause [9]. Group 2: Weight Loss Data - In the PIONEER PLUS phase 3 study, participants taking oral semaglutide lost an average of 9.2 kg (9.54%) and 7.0 kg (7.26%) with 50 mg and 25 mg doses, respectively, over 68 weeks [10]. - The latest OASIS 1 study showed that participants taking 50 mg of oral semaglutide lost an average of 18.34 kg (17.4%) [11]. Group 3: Market Demand and Projections - The demand for GLP-1 receptor agonists like semaglutide is expected to rise significantly due to increasing obesity and type 2 diabetes rates [12]. - The World Health Organization reports that adult obesity rates have more than doubled since 1990, with 8.5% of adults diagnosed with diabetes in 2014 [12]. - GlobalData predicts that by 2033, sales of GLP-1 drugs will reach $168 billion across 68 pharmaceutical markets, with North America accounting for 68% of this revenue [12].